Nebivolol Actavis (Nebivolol Hydrochloride)

Nebivolol is a selective β1‑adrenergic antagonist used in the management of elevated arterial pressure. It helps control blood pressure through vasodilation and reduced cardiac output.

• Essential hypertension: lowers systolic and diastolic blood pressure in adult patients.
• Isolated systolic hypertension: reduces elevated systolic readings while maintaining heart rate.
• Diastolic hypertension: decreases high diastolic pressure to target levels.

• Nebivolol selectively blocks β1‑adrenergic receptors in cardiac tissue, reducing heart rate and myocardial contractility. In addition, it stimulates endothelial nitric oxide synthase, enhancing nitric oxide release and causing vasodilation, which together contribute to a sustained reduction in systemic blood pressure.

Nebivolol may cause a range of adverse reactions, from mild to serious. Awareness of these effects helps clinicians monitor patients appropriately.

Common Side Effects

• Fatigue: feeling unusually tired or weak.
• Headache: mild to moderate cranial pain.
• Dizziness: sensation of light‑headedness, especially on standing.
• Bradycardia: slower than normal heart rate.
• Nausea: upset stomach or urge to vomit.
• Peripheral edema: mild swelling of ankles or feet.

Serious or Rare Side Effects

• Severe bradycardia: markedly low heart rate requiring medical attention.
• Symptomatic hypotension: significant drop in blood pressure causing faintness.
• Atrioventricular block: impaired electrical conduction in the heart.
• Bronchospasm: narrowing of airways, especially in patients with asthma.
• Allergic reactions: rash, itching, or swelling of face and throat.
• Liver enzyme elevation: abnormal liver function tests.

Before initiating Nebivolol therapy, clinicians should assess patient history and monitor for specific concerns.

• Blood pressure monitoring: check baseline and follow‑up readings to gauge effectiveness.
• Cardiac function assessment: evaluate heart rate and rhythm, especially in patients with conduction disorders.
• Liver impairment: use caution and consider dose adjustment in severe hepatic disease.
• Concomitant beta‑blockers: avoid combining with other β‑blockers to prevent excessive bradycardia.
• Discontinuation: do not stop abruptly; taper under medical supervision to avoid rebound hypertension.
• Store at room temperature: keep in the original container, protect from moisture and direct light.

Nebivolol can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid)

• Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): may increase nebivolol plasma levels.
• Other antihypertensives (e.g., ACE inhibitors, diuretics): additive blood‑pressure lowering effect.
• Non‑selective beta‑blockers: risk of excessive β‑blockade and bradycardia.

Moderate Interactions (Monitor Closely)

• Calcium channel blockers (e.g., verapamil): may enhance negative chronotropic effects.
• Anti‑arrhythmic agents (e.g., amiodarone): potential for conduction abnormalities.
• Insulin or oral hypoglycemics: nebivolol can mask hypoglycemia symptoms.
• NSAIDs: may reduce antihypertensive efficacy.
• Antidepressants (e.g., sertraline): monitor for combined central nervous system effects.